AQST Q3 2025 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$13M-5.4% YoY

Gross Profit

$8M64.8% margin

Operating Income

-$11M-89.6% margin

Net Income

-$15M-120.6% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+28.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$164M

Total Liabilities

$168M

Stockholders' Equity

-$4M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$14M	-5.4%
Gross Profit	$8M	$9M	-8.8%
Operating Income	-$11M	-$8M	-38.5%
Net Income	-$15M	-$12M	-34.2%

Revenue Segments

Manufacture and Supply Revenue

$11M90%

License and Royalty Revenue

$1M8%

Co-Development and Research Fees

$302,0002%

Geographic Segments

UNITED STATES

$10M79%

Non-US

$3M21%